Cumberland Pharmaceuticals Said On June 2 FDA Informed Co That It Had Granted A Barrier-to-Innovation Waiver Associated With Reditrex Product Line Which Will Result In Refund Of ~$1.2M Co Paid For Prescription Drug Program Fees For Reditrex Product Line
Portfolio Pulse from Charles Gross
Cumberland Pharmaceuticals announced that the FDA granted a Barrier-to-Innovation Waiver for its Reditrex product line, resulting in a refund of approximately $1.2 million in prescription drug program fees.
June 07, 2023 | 9:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cumberland Pharmaceuticals (CPIX) received a Barrier-to-Innovation Waiver from the FDA for its Reditrex product line, leading to a refund of ~$1.2M in prescription drug program fees.
The FDA's Barrier-to-Innovation Waiver for Cumberland Pharmaceuticals' Reditrex product line will result in a refund of approximately $1.2 million in prescription drug program fees. This refund will positively impact the company's financial position in the short term, potentially leading to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100